Clinical trial NCT06585020: Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection
Official title: Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Mycobacterium; Xenopi
Lung Diseases
Keywords: Mycobacterium; Xenopi
Lung Diseases
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
Collaborators: name: University Hospital, Angers
name: Hospital Avicenne
name: University Hospital, Bordeaux
name: University Hospital, Brest
name: CH Compiègne
name: Créteil Hospital
name: Centre Hospitalier Universitaire Dijon
name: University Hospital, Grenoble
name: Centre Hospitalier le Mans
name: Hôpital de la Croix-Rousse
name: APHM - Nord
name: Hôpital Saint Joseph
name: CH Mulhouse
name: CH Orléans
name: Tenon Hospital, Paris
name: Hôpital Necker-Enfants Malades
name: Centre hospitalier de Perpignan
name: Poitiers University Hospital
name: CH Pontoise
name: CHU de Reims
name: Rennes University Hospital
name: CHU de Rouen - Accueil
name: Central Hospital Saint Quentin
name: IHU Strasbourg
name: University Hospital, Tours
name: CH Abbeville
name: CH Cannes
First posted: 2024-09-05
Enrollment: 190
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Treatment of Mycobacterium xenopi (MX) lung disease is not-well- tolerated and concerned a growing number of patients, especially with chronic pulmonary diseases or immunosuppression. The outcome of these patients is poor, and treatment is very long. Indeed, this duration is based on the date of sputum conversion. Treatment should be continued until 12 months after sputum conversion. In the vast majority patients have converted after 6 months of treatment, so a 18 months duration in total. Unfortunately, few data are available for MX, as it is rare in USA, but it is the second NTM isolated in France and concerns an increasing number of patients. As it is uncommon in USA, no clinical studies conducted by the pharmaceutical laboratory will be planned. In a murine model of MX infection, the only drug which decreased the number colony formant units in mice lungs, was amikacin. Until now, amikacin was only available intravenously and used only for patients with very severe disease, because of renal and auditory toxicity. Amikacin liposome inhalation suspension (ARIKAYCE®) is amikacin sulfate encapsulated in liposomes for inhalational delivery. ARIKAYCE® increases amikacin uptake into alveolar macrophages, a refuge for NTM organisms; allows biofilm penetration; and limits systemic amikacin exposure ARIKAYCE® has already be tested in a randomized study on M. avium complex (MAC) refractory pulmonary infections. In this study, the culture conversion rate in the ARIKAYCE® group was higher than standard regimen group.


Eligibility criteria: Inclusion Criteria:

* 18 years old or older
* with an highly effective or acceptable contraception
* must present ATS/IDSA 2020 criteria for nontuberculous mycobacterial pulmonary infection
* the NTM should be M. xenopi

Exclusion Criteria:

* Patients presenting any of the following criteria cannot be included:
* Known hypersensitivity to one of the molecules of the study
* Relapse of MX lung infection
* Treatment with molecules able to interfere with cytochrome P450 that cannot be replaced by another therapeutic class
* HIV 1 and 2 human immunodeficiency virus infection
* Renal failure with creatinine clearance less than 30 mL/min
* Pregnancy and breastfeeding
* Cystic fibrosis
* Contraindications to one of the antibiotic :

Contraindication to the use of ARIKAYCE®:

* Hypersensitivity to the active substance, to aminoglycosides or to any of the excipients listed in section 6.1 of the CPR.
* Hypersensitivity to soy.
* Co-administration with any other aminoglycoside, regardless of the route of administration
* Severe Renal Failure

Contraindication to the use of Clarithromycine:

Allergy to macrolides or to any of the excipients listed in section 6.1;

* Association with :

  * colchicine,
  * ergot alkaloids, including for example dihydroergotamine, ergotamine, methylergometrine, methysergide: risk of ergotism,
  * pimozide, mizolastine: risk of QT interval prolongation and cardiac rhythm disorders, in particular ventricular tachycardia, ventricular fibrillation and torsades de pointes,
  * simvastatin, due to the increased risk of myopathy, including rhabdomyolysis.
  * lomitapide,
  * alfuzosin
  * dapoxetine
  * avanafil
  * ivabradine,
  * eplerenone,
  * dronedarone,
  * Quetiapine,
  * ticagrelor,
  * cisapride,
  * astemizole,
  * terfenadine,
  * ranolazine,
  * domperidone,
* Congenital or acquired prolongation of the QT interval (see sections 4.4 and 4.5 of the CPR)
* History of QT interval prolongation or ventricular rhythm disorders, in particular torsades de pointe (see sections 4.4 and 4.5 of the CPR);
* Electrolyte imbalances (hypokalaemia or hypomagnesaemia, due to the risk of QT interval prolongation) (see sections 4.4 and 4.5 of the CPR).Clarithromycin should not be used in patients with severe hepatic insufficiency in association with renal insufficiency.

Contraindication to the use of Rifampicine:

* Hypersensitivity to rifamycins or to any of the excipients listed in section 6.1 of the CPR.
* Porphyrias.
* Association with bictegravir, cobicistat, daclatasvir, dasabuvir, delamanid, grazoprevir/elbasvir, ritonavir-boosted protease inhibitors, isavuconazole, lédipasvir, lurasidone, midostaurine, ombitasvir/paritaprévir, praziquantel, rilpivirine, sofosbuvir, velpatasvir, voriconazole, voxilaprévir, (see section 4. 5 of the CPR). In children under 6 years of age, due to the risk of malaria

Contradiction the the use of Ethambutol:

* Known hypersensitivity to ethambutol
* Optic neuritis
* This medicine is contraindicated in patients with a wheat allergy (other than coeliac disease).
* Inability to comply with the requirements of the protocol, especially substance abuse, according to the investigator.
* Limited life expectancy (e.g 3 months)
* Patients with hematologic malignancies and allogeneic haematopoietic stem cells
* Women of childbearing age and not using an effective method of contraception (Pearl Index \<1%)
* The patient is treated with molecules prolonging the QT interval that cannot be replaced by another therapeutic class.
* The patient presents a heart failure with left ventricular ejection fraction less than 30%.

Primary outcomes:
measure: variation of sputum conversion rate in ARIKAYCE® addition group compared to standard treatment
timeFrame: 3 months
Secondary outcomes:
measure: variation of time to culture conversion between both groups
timeFrame: at 3 month
measure: variation of mortality between both groups
timeFrame: at 12 months
measure: variation of mortality between both groups
timeFrame: at 24 months
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens-Picardie
Study officials:
References: